SAN Sanofi

EMA accepts regulatory submission for avalglucosidase alfa, a potentially new standard of care enzyme replacement therapy for Pompe disease

EMA accepts regulatory submission for avalglucosidase alfa, a potentially new standard of care enzyme replacement therapy for Pompe disease
EN
02/10/2020

Underlying

SANSanofi

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Sanofi

 PRESS RELEASE
Free
SAN SANOFI

Press release: Filing of the 2025 U.S. Form 20-F and French “Document ...

Press release: Filing of the 2025 U.S. Form 20-F and French “Document d’Enregistrement Universel” containing the Annual Financial Report Filing of the 2025 U.S. Form 20-F and French “Document d’Enregistrement Universel” containing the Annual Financial Report Paris, February 17, 2026. Sanofi announces today the filing of its Form 20-F with the U.S. Securities and Exchange Commission (SEC) and its “Document d’Enregistrement Universel” containing its Annual Financial Report with the French market regulator Autorité des marchés financiers (AMF). These documents are available on the company’s ...

February 17, 2026 1 EN
 PRESS RELEASE
Free
SAN SANOFI

Communiqué de presse : Dépôt du Document d’Enregistrement Universel 20...

Communiqué de presse : Dépôt du Document d’Enregistrement Universel 2025, contenant le Rapport Financier Annuel, et du « Form 20-F » américain Dépôt du Document d’Enregistrement Universel 2025, contenant le Rapport Financier Annuel, et du « Form 20-F » américain Paris, le 17 février 2026. Sanofi annonce avoir déposé son Document d’Enregistrement Universel 2025 contenant le Rapport Financier Annuel auprès de l’Autorité des marchés financiers (AMF) en France et son « Form 20-F » auprès de la « Securities and Exchange Commission » (SEC) aux Etats-Unis. Le rapport du Conseil d’administration ...

February 17, 2026 1 EN
 PRESS RELEASE
Free
SAN SANOFI

Press Release: Sanofi and Teva’s duvakitug phase 2b maintenance data d...

Press Release: Sanofi and Teva’s duvakitug phase 2b maintenance data demonstrated clinically meaningful durable efficacy in ulcerative colitis and Crohn’s disease Sanofi and Teva’s duvakitug phase 2b maintenance data demonstrated clinically meaningful durable efficacy in ulcerative colitis and Crohn’s disease In the RELIEVE UCCD LTE phase 2b study, duvakitug showed robust, durable efficacy for an additional 44 weeks in UC and CD patients who had responded after 14 weeks of induction Duvakitug was well tolerated and safety was consistent with the induction studyFindings reinforce the potent...

February 17, 2026 1 EN
 PRESS RELEASE
Free
SAN SANOFI

Communiqué de presse : Les données de phase IIb de l’étude d’entretien...

Communiqué de presse : Les données de phase IIb de l’étude d’entretien sur le duvakitug de Sanofi et Teva ont démontré une efficacité durable cliniquement significative dans la colite ulcéreuse et la maladie de Crohn Les données de phase IIb de l’étude d’entretien sur le duvakitug de Sanofi et Teva ont démontré une efficacité durable cliniquement significative dans la colite ulcéreuse et la maladie de Crohn Dans l’étude de phase IIb RELIEVE UCCD LTE, le duvakitug a montré une efficacité robuste et durable pendant 44 semaines supplémentaires chez les patients atteints de CU et de MC qui ava...

February 17, 2026 1 EN
 PRESS RELEASE
Free
SAN SANOFI

Press Release: Beyfortus study published in The Lancet Infectious Dise...

Press Release: Beyfortus study published in The Lancet Infectious Diseases shows benefit for infants beyond first RSV season Beyfortus study published in The Lancet Infectious Diseases shows benefit for infants beyond first RSV season First study showing that infants immunized against RSV in their first season had fewer RSV hospitalizations in their second season The study also showed a reduction of 85.9% in RSV-related lower respiratory tract infection hospitalizations in the first season Data published in The Lancet Infectious Diseases and to be presented at RSVVW ’26 conference in Rom...

February 16, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch